Aspira Women’s Health Announces $5.5 Million Registered Direct Offering and Concurrent Private Placement
January 25, 2024 08:00 ET
|
Aspira Women's Health Inc.
AUSTIN, Texas, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of...
Aspira Women’s Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024
December 19, 2023 08:00 ET
|
Aspira Women's Health Inc.
AUSTIN, Texas, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of...
Aspira Women’s Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024
December 14, 2023 08:00 ET
|
Aspira Women's Health Inc.
Aspira management will be available for meetings in San Francisco (January 8-10, 2024) AUSTIN, Texas, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the...
Aspira Women’s Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis
December 06, 2023 08:00 ET
|
Aspira Women's Health Inc.
Data supports EndoCheck™ to be the first blood test for the identification of localized endometriosis, including endometrioma Platform migration to begin on the Company’s EndoMDx™ test for broader...
Aspira Women’s Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)
November 28, 2023 08:00 ET
|
Aspira Women's Health Inc.
AUSTIN, Texas, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of...
Aspira Women’s Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)
November 27, 2023 09:47 ET
|
Aspira Women's Health Inc.
CMS approves OvaWatchSM 2024 price at $897 per test AUSTIN, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company...
Aspira Women’s Health Reports Third Quarter 2023 Financial Results
November 13, 2023 16:05 ET
|
Aspira Women's Health Inc.
Product revenue increased 9% to $2.2 million for the quarter, and 19% to $7.0 million year to date OvaSuite sales volume increased 5% to 5,783 units for the quarter, and 16% to 18,331 units year...
Aspira Women’s Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch
November 09, 2023 08:00 ET
|
Aspira Women's Health Inc.
The proposed rule would allow for OvaWatchSM to be reimbursed at the same rate as Ova1® at $897 per test and will become final following a brief public comment period AUSTIN, Texas, Nov. 09, 2023 ...
Aspira Women’s Health to Announce Third Quarter Earnings Results and Host a Conference Call on Monday, November 13, 2023
October 31, 2023 08:00 ET
|
Aspira Women's Health Inc.
AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools...
Aspira Women’s Health Sees Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research
October 25, 2023 08:00 ET
|
Aspira Women's Health Inc.
AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of...